NCT05184049

Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients

Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patient

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Xiangya Hospital of Central South University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study evaluated the efficacy of epalrestat in diabetic peripheral neuropathy and its effects on the central nervous system in diabetic peripheral neuropathy subjects.

Conditions

• Diabetes

Interventions

Type	Name	Description
DRUG	Epalrestat,Mecobalamin	Epalrestat will be taken orally at a dose of 50mg 3 times a day before meals. In addition, conventional hypoglycemic and oral mecobalamin treatment 0.5mg/ time, 3 times/day, before meals.
DRUG	Mecobalamin	Subjects takes mecobalamin 0.5mg orally, 3 times a day.Regular hypoglycemia.

Timeline

• Start date: 2022-01-01
• Primary completion: 2023-10-01
• Completion: 2023-10-01
• First posted: 2022-01-11
• Last updated: 2022-01-11

Locations

1 site across 1 country: China